logo-loader
Avacta Group PLC

Avacta Group Plc - On track and undervalued

At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeutic and reagents programs.

Their lead immuno-oncology development program is proceeding according to plan and multiple development milestones are expected in the course of 2018 (see next section for further details).

Executive summary

We look at Avacta using a SOTP approach that considers separately the therapeutic programs and the reagents business.
 
Essentially we work out "backwards" what the implied equity value should be today, assuming Affimer products reach certain commercial levels ten years from now

Quick facts: Avacta Group PLC

Price: £0.22

Market: AIM
Market Cap: £26.02 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

4 min read